无创心肌做功技术在乳腺癌患者双靶向治疗相关心脏毒性早期评估中的研究进展OA

With the widespread application of human epidermal growth factor receptor 2(HER2)targeted dual therapy in breast cancer treatment,related cardiotoxicity issues are increasingly becoming a pressing challenge to be addressed clinically.Non-invasive myocardial work(MW)technology,an emerging evaluation tool based on echocardiographic pressure-strain loops,shows potential in the early diagnosis of cardiotoxicity in breast cancer patients.This article systematically reviews the potential mechanisms of cardiotoxicity related to HER2-targeted dual therapy in breast cancer and the limitations of existing diagnostic and treatment methods.The theoretical basis,measurement methods,and core parameters of non-invasive myocardial work technology are discussed in depth.Based on the latest literature,this article analyzes the sensitivity and specificity advantages of non-invasive myocardial work technology in the early identification of cardiotoxicity,comparing it with traditional assessment markers.Additionally,the preliminary clinical application results of this technology in dynamically monitoring changes in heart function and guiding individualized treatment adjustments are summarized.Current studies indicate that non-invasive myocardial work technology outperforms traditional methods in the early detection of cardiotoxicity related to HER2-targeted dual therapy in breast cancer,with higher sensitivity and broader prospects.However,most current studies are small-scale,single-center exploratory studies,and higher-level clinical evidence is needed for validation.Future research should focus on multi-center,large-scale,prospective clinical trials,standardizing measurement processes,and actively exploring AI-assisted analysis and multi-modal imaging integration,with the goal of incorporating this technology into the clinical decision-making pathway of cardio-oncology and related guidelines.